Dr. Perl on Survival Improvement With Gilteritinib in FLT3+ AML
April 12th 2019Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.
Watch
Updates to NCCN Guidelines on Molecular Assays for Patients With Breast Cancer
April 8th 2019William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.
Watch
Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical Cancer
April 1st 2019<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.</p>
Watch
Dr. Posadas Discusses Darolutamide in Castration-Resistant Prostate Cancer
March 29th 2019Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
Watch